JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17

JP Morgan analyst Brian Cheng has initiated coverage on AbCellera Biologics (NASDAQ: ABCL) with an Overweight rating. The firm has set a price target of $17 for the company's stock.